Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05921448 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Study acronym: VAXXAIR
StatusActive, Not Recruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2026 (before its estimated July 27, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark to Copenhagen Respiratory Researchv6 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Apr 30, 2026 to Jul 27, 2026
    • Start date changed from estimate of Aug 1, 2025 to May 19, 2025
    • Site contacts updated at 1 of 7 sites
  2. Start date: May 1, 2024 to Aug 1, 2025
    • Site details revised at 3 of 7 sites
    v5
  3. Start date: Jan 1, 2024 to May 1, 2024v4 Show 7 more changesShow less
    • Primary endpoints: 2 to 1
    • Study sites: 6 to 7
    • Primary and study completion dates: Dec 31, 2025 to Apr 30, 2026
    • Eligibility criteria expanded, about 41 words
    • Secondary endpoints: 2 to 6
    • Study description revised
    • Study title revised
  4. Primary endpoints revised (2)
    • Secondary endpoints expanded, about 18 words
    • Eligibility criteria expanded, about 5 words
    v3
  5. Eligibility criteria shortened, about 1 wordv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research.
Trial Details
NCT Number NCT05921448
Lead Sponsor Copenhagen Respiratory Research
Collaborators: The Novo Nordic Foundation
Conditions
(from sponsor)		 Influenza, Human
Related terms Influenza, Human
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov